Alvocidib
chemical compound
Alvocidib (INN; also known as flavopiridol) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation. The target of alvocidib is the positive transcription elongation factor P-TEFb. Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production.
The compound is a synthetic analog of natural product rohitukine which was initially extracted from Aphanamixis polystachya (formerly Amoora rohituka, hence the name) and later from Dysoxylum binectariferum.
Orphan drug
The FDA has granted orphan drug designation to alvocidib for the treatment of patients with acute myeloid leukemia.
The public source identifies “Alvocidib” as chemical compound. This brief keeps that definition visible, then builds a research path around Alvocidib, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Alvocidib”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Dec 29, 2025. The linked authority identifier is Q4063441. None of the 0 selected statements returned an explicit reference.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Alvocidib”, its source revision and the description used here.
- Expand the search: follow Alvocidib primary sources, Alvocidib archive and Alvocidib research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Alvocidib”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Alvocidib” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.